Do Swedencare's (STO:SECARE) Earnings Warrant Your Attention?
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Has the Swedish Pharma Industry valuation changed over the past few years?
|Mon, 24 Jan 2022||kr49.1b||kr5.5b||-kr1,083,939,448.00||112.1x|
|Wed, 22 Dec 2021||kr55.2b||kr5.5b||-kr1,100,338,740.00||112.9x|
|Fri, 19 Nov 2021||kr59.3b||kr5.3b||-kr1,355,585,770.00||88x|
|Sun, 17 Oct 2021||kr52.9b||kr4.8b||-kr1,581,702,061.00||140.1x|
|Tue, 14 Sep 2021||kr57.5b||kr4.8b||-kr1,560,489,765.26||153.5x|
|Thu, 12 Aug 2021||kr55.4b||kr4.8b||-kr1,412,039,942.26||162.8x|
|Mon, 07 Jun 2021||kr53.2b||kr4.6b||-kr1,469,283,209.50||173.3x|
|Sun, 28 Feb 2021||kr51.4b||kr4.5b||-kr1,418,962,725.57||160.1x|
|Wed, 02 Dec 2020||kr51.0b||kr4.4b||-kr913,043,309.17||81.6x|
|Sat, 05 Sep 2020||kr45.6b||kr4.1b||-kr535,762,892.63||26x|
|Tue, 09 Jun 2020||kr35.5b||kr3.7b||-kr414,746,201.62||28.4x|
|Mon, 02 Mar 2020||kr28.3b||kr3.3b||-kr382,446,640.84||22.7x|
|Thu, 05 Dec 2019||kr27.4b||kr3.0b||-kr628,422,177.00||40.6x|
|Sun, 08 Sep 2019||kr25.2b||kr2.9b||-kr521,071,289.00||31.8x|
|Sat, 01 Jun 2019||kr26.1b||kr3.3b||kr13.0m||14.8x|
|Tue, 05 Mar 2019||kr23.9b||kr2.6b||-kr83,038,134.00||15.2x|
Current Industry PE: Investors are more optimistic on the industry, considering it's trading at a PE ratio of 112x which is higher than its 3-year average PE of 73.5x. It appears they are confident that earnings will grow faster in the future than they have historically.
Past Earnings Growth: The earnings for companies in the Pharmaceuticals industry have deteriorated over the last three years, while revenues for these companies have grown 27% per year. This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Which industries have driven the changes within the Swedish Pharma industry?
Industry PE: Investors are most optimistic about the Pharma industry which is trading above its 3-year average PE ratio of 73.5x. This is likely because analysts are expecting annual earnings growth of 27%, which is higher than its past year's earnings decline of 26% per year.
Forecasted Growth: Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 27% over the next 5 years. This is better than its past earnings decline of 26% per year.
Which companies have driven the market over the last 7 days?
Infant Bacterial Therapeutics
InDex Pharmaceuticals Holding